SAR405838

Sanofi · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	SAR405838
Sponsor	Sanofi
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1 Safety Testing of SAR405838 (PHASE1)
A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SAR405838 CI brief — competitive landscape report
SAR405838 updates RSS · CI watch RSS
Sanofi portfolio CI